FDA ZYN Nicotine Pouch Authorization: 2026 Update
Short answer: the FDA ZYN nicotine pouch authorization now has two distinct layers. On January 16, 2025, the FDA authorized the marketing of 20 ZYN products through the premarket tobacco product application (PMTA) pathway. On June 30, 2026, the agency issued modified risk granted orders for those same 20 products, allowing one specific lower-risk claim when ZYN is used instead of cigarettes. Neither decision means ZYN is "FDA approved" or safe.
- The authorization covers 10 named ZYN flavors in 3 mg and 6 mg strengths, for 20 products in total.
- The modified risk order permits an exact claim about using ZYN instead of cigarettes; it is not a blanket claim that nicotine pouches are harmless.
- As of August 4, 2026, the FDA lists 30 authorized nicotine pouch products: 20 ZYN products and 10 products sold under the on! and on! PLUS brands.
What Is the FDA ZYN Nicotine Pouch Authorization?
People searching for "FDA ZYN nicotine pouch authorization" are often looking for a yes-or-no answer: did the FDA approve ZYN? The legally accurate answer is more specific. The FDA has issued marketing granted orders that authorize 20 named ZYN nicotine pouch products to be sold in the United States. It has also issued separate modified risk granted orders that authorize those products to carry one specific risk modification claim.
These are tobacco-product marketing orders, not drug approvals, and they do not authorize ZYN as a smoking-cessation medicine. The FDA's current authorized nicotine pouch list explicitly says that authorized products are not "FDA approved" and are not safe.
ZYN FDA Authorization Timeline
| Date | FDA action | What it means |
|---|---|---|
| January 16, 2025 | PMTA marketing authorization for 20 ZYN products | The listed products may be lawfully marketed in the United States, subject to the orders and other applicable law. |
| June 30, 2026 | Modified risk granted orders for the same 20 ZYN products | The products became the first nicotine pouches permitted to use an FDA-authorized modified risk claim. The orders last five years and impose postmarket surveillance requirements. |
| August 4, 2026 | Four additional on! products receive PMTA marketing authorization | The FDA's authorized nicotine pouch list grows to 30 products. The new on! orders do not include ZYN's modified risk claim. |
Which ZYN Products Are FDA Authorized?
The FDA's product-by-product MRTP order table confirms 10 flavors, each in 3 mg and 6 mg nicotine strengths:
- Chill
- Cinnamon
- Citrus
- Coffee
- Cool Mint
- Menthol
- Peppermint
- Smooth
- Spearmint
- Wintergreen
The product-specific wording matters. The orders do not automatically extend to every ZYN flavor or strength, to future ZYN releases, or to the nicotine pouch category as a whole.
What Modified Risk Claim Did the FDA Authorize?
According to the FDA's June 30, 2026 announcement, the authorized wording is:
“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
The comparison and the behavior in that sentence are essential. It refers to using the authorized ZYN products instead of cigarettes. It is not permission to say that ZYN has no risk, that nicotine is not addictive, or that every user will receive the same outcome. The FDA states that there is no safe tobacco product and that people who do not use tobacco products should not start.
The orders expire after five years unless renewed. Swedish Match USA must also conduct postmarket surveillance and studies, including assessments of user behavior and understanding of the claim. The FDA can withdraw the orders if continued marketing no longer benefits population health as a whole.
PMTA vs. MRTP: Why ZYN Has Two FDA Decisions
| Pathway | Question the FDA decides | What an order permits |
|---|---|---|
| PMTA | Is marketing the specific new tobacco product appropriate for the protection of public health? | The specific product may be legally marketed, subject to the order and applicable restrictions. |
| MRTP | Does the evidence support marketing the specific product with a proposed modified risk claim? | The specific product may use the exact authorized claim under the conditions and time limit in the order. |
In other words, authorization to sell came first. Authorization to communicate the specific modified risk claim came about 17 months later. Calling both decisions simply "FDA approval" erases the distinction readers most need to understand.
Latest Update: The FDA List Now Contains 30 Nicotine Pouches
The regulatory picture changed again on August 4, 2026. The FDA authorized four on! nicotine pouches made by Helix Innovations LLC: Rich Berry 2 mg, Cappuccino 2 mg, Cappuccino 4 mg, and Autumn Spice 2 mg. Those products joined six previously authorized on! PLUS products.
That brings the current FDA total to 30 authorized nicotine pouch products: 20 made by Swedish Match USA and sold as ZYN, plus 10 made by Helix and sold as on! or on! PLUS. This latest development, also summarized by 2Firsts, means it is no longer accurate to say ZYN is the only nicotine pouch brand with FDA marketing authorization.
The distinction still matters: the four new on! products received PMTA marketing authorization, not modified risk granted orders. The August 4 orders do not authorize those products to use the ZYN-specific lower-risk claim. The FDA also said it has started applying efficiencies learned from its nicotine pouch pilot program to other PMTA reviews, while continuing to review products case by case against the applicable statutory standard.
Does the ZYN Authorization Apply to Other Brands?
No. FDA tobacco product orders apply to the products named in the orders, not to an entire category. ZYN's orders do not automatically confer authorization on a similar product from another manufacturer. A different product cannot be described as FDA authorized, or use ZYN's modified risk claim, solely because it resembles an authorized ZYN product.
As of the FDA list dated August 4, 2026, Zar nicotine pouches are not among the 30 authorized nicotine pouches. Regardless of a product's design attributes, only a product-specific FDA order establishes U.S. marketing authorization or permission to use a modified risk claim.
Why the Authorization Matters
The ZYN decisions establish a public, product-specific example of how the FDA evaluates nicotine pouches under two different statutory pathways. For consumers, the decisions make it easier to separate lawful marketing authorization from broad claims of safety. For manufacturers, they show that formulation data, toxicology, consumer understanding, youth-risk analysis, population modeling, and postmarket monitoring all form part of the regulatory picture.
The August 2026 on! authorizations add another signal: the category is no longer represented by a single authorized brand, and the FDA is applying lessons from its review pilot more broadly. But the central rule has not changed. Shelf presence, brand recognition, and product similarity do not create authorization. The FDA's orders identify the products that may be marketed and the claims they may make.
Frequently Asked Questions
Is ZYN FDA approved?
No. The FDA has authorized 20 specific ZYN products for marketing and has separately authorized one modified risk claim for those products. The agency says authorized nicotine pouches are not "FDA approved" and are not safe.
When did the FDA authorize ZYN nicotine pouches?
The FDA issued PMTA marketing orders on January 16, 2025. It issued modified risk granted orders on June 30, 2026.
How many ZYN products are FDA authorized?
Twenty: 10 named flavors, each in 3 mg and 6 mg strengths.
How many nicotine pouches has the FDA authorized in total?
As of August 4, 2026, the FDA lists 30 authorized nicotine pouch products: 20 ZYN products and 10 on! or on! PLUS products.
Does FDA authorization mean nicotine pouches are safe?
No. Nicotine is addictive, and the FDA states that there is no safe tobacco product. People who do not currently use tobacco products should not start.
For adults 21+ in the United States. Contains nicotine. Nicotine is an addictive chemical.
Primary sources: U.S. Food and Drug Administration, January 16, 2025 ZYN PMTA announcement; June 30, 2026 ZYN MRTP announcement; product-level MRTP orders; August 4, 2026 on! PMTA announcement; and the current authorized nicotine pouch list.
Cross-checks: Philip Morris International's January 2025 product list and July 2026 MRTP summary; and 2Firsts' August 2026 regulatory update.